Hemogenyx Pharmaceuticals PLC Posting of Annual Report & Notice of AGM (4119Q)
06 June 2018 - 3:05AM
UK Regulatory
TIDMHEMO
RNS Number : 4119Q
Hemogenyx Pharmaceuticals PLC
05 June 2018
Hemogenyx Pharmaceuticals Plc
("Hemogenyx" or the "Company")
Posting of Annual Report
& Notice of Annual General Meeting
Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology
company developing novel therapies to transform bone marrow, or
blood stem cell, transplantation for the treatment of blood
diseases, confirms that the Annual Report and Accounts for the year
ended 31 December 2017 ("2017 Annual Report"), the Notice of the
Annual General Meeting and a Form of Proxy are now available on the
Company's website:
https://www.hemogenyx.com/investors/annual-and-half-year-reports/default.aspx
The 2017 Annual Report will be posted to shareholders today.
The AGM is to be held on 27 June 2018 at 11am at the offices of
Charles Russell Speechlys LLP, 5 Fleet Place, London, EC4M 7RD.
Enquiries:
Hemogenyx Pharmaceuticals Limited www.hemogenyx.com
Dr Vladislav Sandler, Chief Executive Via Walbrook PR
Officer & Co-Founder
Sir Marc Feldmann, Executive Chairman
Optiva Securities Ltd Tel: +44 (0)20 3137
1902
Christian Dennis
Shard Capital Partners LLP Tel: +44 (0)20 7186
9950
Damon Heath, Erik Woolgar
Peterhouse Corporate Finance Limited Tel: +44 (0)20 7469
0930
Lucy Williams, Duncan Vasey
Walbrook PR (UK Media & Tel: +44 (0)20 7933 8780 or
Investor Relations) hemogenyx@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
US Media enquiries
Lowell Goodman Tel: +1 (323) 646-3249 or Lowell@corbomitecomms.com
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE:
HEMO) headquartered in London, with its wholly owned U.S. operating
subsidiary, HemoGenyx LLC, located in its state-of-the-art research
facility in Brooklyn, New York. HemoGenyx is a preclinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel therapies and treatments for blood
diseases such as leukemia and lymphoma. The company's leading
technologies aim to change the way in which bone
marrow/hematopoietic stem cell (BM/HSC) transplants are performed
and improve their efficacy. HemoGenyx's two distinct and
complementary products include an immunotherapy product for patient
conditioning-the CDX bi-specific antibody-and a cell therapy
product for BM/HSC transplantation-the HuPHEC. Each of these
products holds the potential to revolutionize the way BM/HSC
transplants are being performed, offering solutions that mitigate
the dangers and limitations associated with the current standard of
care. For more information, visit www.hemogenyx.com.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCFAMRTMBMMBIP
(END) Dow Jones Newswires
June 05, 2018 13:05 ET (17:05 GMT)
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From Apr 2024 to May 2024
Hemogenyx Pharmaceuticals (LSE:HEMO)
Historical Stock Chart
From May 2023 to May 2024